Objective: Cyclooxygenase-2 (COX-2) is induced by hypoxic stimuli and is also involved in the process of angiogenesis. We previously demonstrated that vascular endothelial growth factor (VEGF) is one of the principal factors produced by hypoxic myocytes and is responsible for the induction of COX-2 expression in endothelial cells. Yet the signaling pathways by which VEGF modulates COX-2 gene expression are still less well defined. We therefore examined the regulation of VEGF-induced COX-2 expression by the mitogen-activated protein kinase (MAPK) family in endothelial cells. Methods and results: Human umbilical vascular endothelial cells (HUVECs) were incubated with U0126 (ERK1/2 inhibitor, 10 AM), SB203580 (p38 inhibitor, 20 AM), and SP600125 (JNK inhibitor, 20 AM), as well as the COX-2 selective inhibitor, NS398, for 1 h before treating with VEGF (20 ng/ml). COX-2 expression induced by VEGF at both mRNA and protein levels was significantly inhibited by selective p38 and JNK inhibitors but not by the ERK1/2 inhibitor. The phosphorylation of p38 and JNK kinases was observed as early as 5 min in HUVECs after VEGF stimulation. Furthermore, the biological significance of the COX-2 gene in endothelial cells was examined by over-expressing or knocking down COX-2 gene expression.
Introduction
Cyclooxygenase (COX) is the rate-limiting enzyme in the biosynthesis of prostaglandins. There are two main isoforms of COX identified so far. COX-2 is an early response gene and induced by many pro-inflammatory cytokines, including VEGF and IL-1h, whereas COX-1 is constitutively expressed in most of the tissues [1] . Recent evidence demonstrates that the production of pro-steroids by COX-2 promotes the expression of pro-angiogenic factors [2] . Inhibition of COX-2 by non-steroidal anti-inflammatory drugs leads to restricted angiogenesis and down-regulates production of pro-angiogenic factors, such as VEGF and basic fibroblast growth factor (FGF-2) [3] . Recently, COX-2 inhibitors (Celebrex, Bextra, etc.) have been withdrawn from the market because these popular painkillers may increase the risk of heart attacks [4] [5] [6] , strokes and other cardiovascular problems [7, 8] . However, since there is no clear evidence suggesting the mechanism of COX-2 involved in cardiac protection, COX-2 is still argued as a pro-inflammatory agonist and a suitable target for the treatment of chronic inflammatory disease. Thus, it is imperative to understand the molecular mechanisms regulating COX-2 expression in cardiovascular disorders.
Hypoxia-induced gene products that result in new vessel growth or angiogenesis may be part of a self-regulated physiological protection mechanism preventing cell injury, especially under conditions of chronic ischemia [9] . Among various angiogenesis-stimulating factors, VEGF is one of the most effective and predominant. Previously, we confirmed that the expression of COX-2 in endothelial cells is induced by hypoxia-stimulated VEGF secretion from cardiac myocyte, suggesting that VEGF may regulate COX-2 expression [10] . It has been reported that VEGF can activate various signaling pathways, such as MAPK, PI3K and PKC [11 -13] . Activation of MEK1-ERK1/2 signaling is essential for VEGF-mediated proliferation and migration of endothelial cells [14] . In addition, activation of the tyrosine kinase receptor, vascular endothelial growth factor receptor 2 (VEGFR2) by VEGF leads to the activation of stressactivated protein kinase SAPK2/p38. The phosphorylation of tyrosine 1214 on VEGFR2 is required to trigger the sequential activation of Cdc42 and SAPK2/p38 and to drive the SAPK2/p38-mediated actin remodeling in stress fibers in endothelial cells exposed to VEGF [15] .
Recently, we demonstrated that eNOS and PKC were required for the induction of COX-2 expression [10] . In this report, we have further analyzed the involvement of MAP kinase family members in VEGF-stimulated COX-2 expression in HUVECs, which are most often used for in vitro studies of inflammation and angiogenesis [16] . We also examined the importance of the role of COX-2 in VEGFinduced angiogenesis. Our results suggested that VEGFactivated pathways of p38 and JNK kinases are necessary for COX-2 expression in endothelial cells. Importantly, COX-2 is one of the key molecules in VEGF-induced angiogenic reaction. Therefore, the treatment of COX-2 inhibitor may block the angiogenic effect of COX-2 and thus, increase the risk of cardiovascular events.
Materials and methods

Cell culture
HUVECs (Clonetics Corporation, San Diego, CA) were cultured in Endothelial cell Basal Medium-2 (EBM-2) supplemented with 100 units/ml penicillin, 100 Ag/ml streptomycin and EGM-2 bullet kit (Clonetics Corporation, San Diego, CA). HUVECs were grown up to 85 -90% confluence and then transferred to serum and bullet kit free medium overnight before being used for experiments as indicated. The authors have read and approved of the Declaration of Helsinki for medical research involving human material.
RNA isolation and Northern blot
The cDNA probes of COX-1 and COX-2 were made by RT-PCR protocol. The primers for RT-PCR were designed according to the published human cDNA sequences. The COX-1 sequence of forward 5V-TCATCGAGGAG-TACGTGC AG-3V, corresponding to bases 1080 -1099 and reverse 5V-AGGGACAGGTCTTGGTGTTG-3V, corresponding to bases 1759 -1778 were used to amplify the 661-bp COX-1 fragment. The COX-2 sequence of forward 5V-TAAACTGCGCCTTTTCAAGG-3V, corresponding to bases 781 -800 and reverse 5V-GTGATACTTTCTG-TACTGCG-3V, corresponding to bases 1381 -1400 were used to amplify the 620bp COX-2 fragment. Total RNA was obtained from cultured HUVECs by Tri-Reagent protocol (Sigma, St. Louis, MO), as previously described [10] . The RNA was fractionated on a 1.3% formaldehyde-agarose gel and transferred to GeneScreen Plus membrane (New England Nuclear, Boston, MA). The a 32 P-dCTP labeled COX-1 and COX-2 probes were hybridized in QuikHyb solution (Stratagene, La Jolla, CA). Autoradiographical signals were quantified by densitometry using ImageQuant software and adjusted by the density of 28S.
Protein extraction and Western blotting
Total cell lysates from cells were subjected to 10% SDS-PAGE electrophoresis and subjected to Western blot analyses as previously described [10] . Protein extracts were transferred to PVDF-membranes (Millipore Co., Bedford, MA). The following antibodies were applied to the study: Anti-COX-1 (Calbiochem, La Jolla, CA), COX-2 (Cayman Chemical, Ann Arbor, MI), p38 MAP kinase, phospho-p38 MAP kinase, SAPK/JNK and phospho-SAPK/JNK (Cell Signaling Technology), as well as h-actin (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies. Immunoblots were visualized by ECL Western blotting detection reagents (Amersham Life Science, Arlington Heights, IL). Autoradiographical signals were quantified by densitometry using ImageQuant software and adjusted by the density of h-actin.
MAPK signal pathway investigation
Selective ERK1/2 inhibitor-U0126, selective p38 MAP kinase inhibitor-SB203580 and selective JNK inhibitor-SP600125 (Alexis, San Diego, CA) were used to pre-treat HUVECs for 60 min, before continuing to incubate HUVECs with addition of VEGF 20 ng/ml (Genetech, Inc., Sage Brush Trail Plano, TX) for another 3 h. Total RNA and protein were extracted at the completion of experiments and COX-1, COX-2 mRNA and protein expression were investigated respectively. To further investigate the VEGF-induced MAP K phosphorylation in vascular endothelial cells, HUVECs were incubated with VEGF (10 ng/ml) and protein lysate was prepared in sampling buffer (1 Â SDS, 10 mM sodium fluoride, 10 mM sodium vanadate) in harvested cell at 5, 10, 20, 30 and 60 min. Western blot with anti-phospho-p38 and phospho-JNK were performed. Autoradiographical signals were quantified by densitometry using ImageQuant software and adjusted by the density of h-action.
COX-2/pEGFP-N1 plasmid construct and siRNA design, synthesis and transfection
Based on published human COX-2 cDNA sequence (GeneBank access: M90100.1), two primers were designed to tag with Xhol-1 and Kpn-1 restriction sites: sense-CAG ATC TCG AGT CAG ACA GCA AAG CCT ACC C, antisense-CCC GCG GTA CCG TCA GTT CAG TCG AAC GTT CT, in which the COX-2 stop codon was excised. COX-2 insert was then prepared by PCR. The pEGFP-N1 vector (Clontech, Palo Alto, CA) was cut with Xhol-1 and Kpn-1, followed by the insertion of 1812-bp human COX-2 upstream of GFP in pEGFP-N1 expression vector. COX-2/ pEGFP-N1 construct was transfected into HUVECs using Lipofectamine reagent (Invitrogen, Carlsbad, CA).
The siRNA sequence used for targeted silencing of human COX-2 was designed by Qiagen software. A COX-2 siRNA targeting the specific sequence AAATTGCTGG-CAGGGTTGCTG was selected for this study. Searches of the human genome database (BLAST) were carried out to ensure that the sequence would not target other gene transcripts. Non-silencing control siRNA is an irrelevant siRNA with random nucleotides and no known specificity. Sequences were synthesized and annealed by the manufacturer (Qiagen, Valencia, CA). COX-2 siRNA was transfected into HUVECs following manufactory the siRNA transfection protocol (Targeting Systems, Santee, CA).
Matrigel morphogenetic assay
100 Al Growth Factor Reduced MATRIGEL Matrix (GFR Matrigel)(BD Biosciences, Bedford, MA) was added to 24-well plate, and incubated at 37 -C for 30 min to allow thin gel formation. HUVECs (5 Â 10 5 /well) were plated onto Matrigel in each well. After 24-h incubation in 5% CO 2 humidified atmosphere at 37 -C, the three-dimensional organization of the cells was examined under an inverted phase contrast photomicroscope (Nikon, TS100 model, Japan) and then photographed for further angiogenesis analysis using Image J1.29 software (from NIH homepage). The average number of tubule formations in randomly selected from 5 high-power field (Â 40) views of 3D-conditioned assays were counted and compared. Differences between the numbers of tubule formations in 3D-conditioned Matrigel assays were subject to Student's t-test analysis.
Cell proliferation assay by 3 H-thymidine incorporation
HUVECs were cultured in 12-well plate. At the completion of experiment, cells were washed with 1 Â PBS PBS 2 times and then incubated with 3 H-thymidine (NEN, Boston, MA) (1 Al/ml medium) for 4 h at 37 -C. Thereafter, 0.5 ml cold 10% Trichloroacetic acid (TCA) was added into each well for another 30 min at 4 -C. Cells were washed once with cold 10% TCA. To extract 3 H-thymidine labeled DNA, 0.5 ml 1N NaOH was added to each well for 10 min at room temperature, and then 0.5 ml 1N HCl was added and mixed well. 0.4 ml mixture solution was taken in each well and added to scintillation vials for the measurement of 3 H-thymidine uptake (cpm). Data were expressed as the percentage of control.
Statistical analysis
Comparisons between groups were carried out by Student's t-test for multiple comparisons where appropriate. Data are presented as ''% of control''.
Results
Inhibition of either p38 or JNK MAPK pathway suppresses the COX-2 expression induced by VEGF in HUVECs
COX-2 expression, but not COX-1, was remarkably enhanced by the stimulation of VEGF in HUVECs. However, VEGF-induced COX-2 expression, at both mRNA and protein levels, was significantly down-regulated in the presence of either p38 MAP kinase selective inhibitor, SB203580; or JNK selective inhibitor, SP600125 in HUVECs, whereas ERK1/2 selective inhibitor, U0126, did Fig. 2 . VEGF-induced p38 MAP kinase and JNK phosphorylation in HUVEC. HUVEC cells were treated with VEGF at a time-dependent manner and the cell lysate was prepared by sampling buffer (1 Â SDS, 10 mM sodium fluoride, 10 mM sodium vanadate) and then subject to Western blot analysis with antibodies against phospho-and nonphospho-forms of p38 or phospho-and nonphospho-form of JNK MAPK. Autoradiographic signals were quantified by densitometry using ImageQuant software. Quantitative analyses are shown on lower panel phopho-p38 vs. p38 (left) and phospho-JNK vs. JNK (right) with adjusted by the ratio of density of h-action. Note VEGF stimulates both p38 and JNK phosphorylation at 10 and 20 min. in HUVEC cells. not cause any effect on its regulation, when compared to control (Fig. 1A) . In contrast, the treatment of above selective inhibitor did not affect the expression of COX-1, an isoform of Cyclooxygenase that is constitutively expressed in most of human tissues, suggesting that p38 MAPK and JNK pathways were specifically involved in the up-regulation of COX-2 gene expression by VEGF. In addition, a dose-response of VEGF-induced COX2 expression to p38 MAPK and JNK specific inhibitors was also found in HUVECs (Fig. 1B) . 
VEGF activates both p38 and JNK MAPK phosphorylation in HUVECs
After exposure to VEGF (10 ng/ml) for various periods of time (Fig. 2) , the HUVECs were harvested and their activity for two MAP kinases, p38 and JNK, were measured. As shown in Fig. 2 , VEGF significantly triggered a transient phosphorylation of p38 MAPK and JNK, which reached a peak of 2.5-fold over the basal level after 20 min of stimulation.
Involvement of COX-2 expression in VEGF-induced angiogenesis in vitro
was blocked by its specific inhibitor, NS398 (Fig. 3A , p < 0.05).
To further investigate the involvement of COX-2 in VEGF-induced cellular proliferation, HUVECs were transfected with either COX-2/pEGFP-N1 construct or COX-2/ siRNA before subjecting to 3 H-thymidine incorporation. Western blotting analysis indicated that transfection of siRNA targeting COX-2 significantly reduced the expression of COX-2 (Fig. 3B) . As Fig. 3C shows, the DNA synthesis was significantly improved in COX-2 overexpressed HUVECs compared to control ( p < 0.05), meanwhile the exogenous VEGF stimulation obviously enhanced this performance ( p < 0.05). On the contrary, the VEGFinduced 3 H-thymidine incorporation was reduced by 34.12 T 5.81% with the transfection of COX-2/siRNA. Therefore, COX-2 seems to be an important gene in the regulation of VEGF-induced cell proliferation in vascular endothelial cells.
For the comprehensive understanding of COX-2 action in VEGF-related angiogenesis, HUVECs were seeded on an artificially set matrix (Matrigel) after transfection with either COX-2/pEGFP-N1 or COX-2/siRNA to test the formation of capillary-like tubular structures mimicking vessel formation with and without VEGF stimulation. As a result, impairment of tubule formation was already evident in COX-2-siRNA transfected cells (Fig. 4C) . Moreover, in the combination of VEGF stimulation, the number of tubulelike structures in such HUVECs was significantly reduced compared to that obtained from control (Fig. 4A,B) . On the other hand, in this functional assay, the higher number of tube-like formation was found in COX-2 over-expressed HUVECs in the addition of VEGF (Fig. 4E,F) , in accordance with cell proliferation data as previously described in 3 H-thymidine incorporation test (Fig. 3A) .
Discussion
This study clearly demonstrates that VEGF-induced upregulation of COX-2 depends on p38 MAPK and JNK signaling pathways. We showed that induction of COX-2 by VEGF was inhibited by the treatment of HUVECs with SB203580 and SP600125, a potent selective p38 and JNK inhibitor, respectively. Combined with the phosphorylation of p38 and JNK induced by VEGF stimulation, our data strongly suggest that activation of p38 and JNK pathways is critical for the COX-2 induction in human vascular endothelial cells. It is already known that p38 pathway may convey the VEGF signal to microfilaments, inducing rearrangements of the actin cytoskeleton that regulate cell migration [17] . On the other hand, in the model of skin cancer cells, MAPKs, specifically p38 and JNK, appear to play a major role in the expression of UVA-induced COX-2 [18] . However, our study revealed for the first time the signal pathways by which VEGF induces COX-2 expression in endothelial cells.
Interestingly, activation of PKC and iNOS was also found to be required for VEGF-induced COX-2 expression [10] , indicating that there are multiple pathways involved in the induction of COX-2 expression by VEGF. Since it has been reported that VEGF-induced MAPK activation was PKC-dependent [19] , it was unexpected that MAPK inhibitor did not affect VEGF-induced COX-2 expression (Fig. 1A) while PKC inhibitor did. It will be interesting to know whether or not there exists a PKC-dependent but MAPK independent pathway regulating VEGF-induced COX-2 expression in endothelial cells.
Importantly, we found that COX-2 gene was physiologically involved in VEGF-induced angiogenic response in cultured HUVEC cells. VEGF-induced cell proliferation and tube formation significantly decreased when HUVECs were either pre-treated with COX-2 inhibitor NS398 (21.52 T 3.6%) or transfected with COX-2-siRNA (34.12 T 5.81%), indicating that COX-2 is at least partially involved in these biological processes. Our data implicates that COX-2 may play an important role in VEGF-induced angiogenesis in vivo. This finding reveals a therapeutically potential role of COX-2 inhibitor as an anti-tumor drug. It has been extensively studied that VEGF is involved in tumor-related angiogenesis. Since COX-2-dependent prostaglandins production can stimulate VEGF expression in tumor cells, COX-2 may function in angiogenic process as a positive-feedback loop between tumor cells and endothelial cells. Inhibition of COX-2 may block such a feedback loop and thus inhibit angiogenesis-dependent tumor growth.
Cheng et al. [20] demonstrated that treatment of the cells overexpressing COX-2 with a COX-2-selective inhibitor, NS-398 (10 mM), also decreased PGE2 level and attenuated VEGF expression. Up-regulation of COX-2 correlates with VEGF expression and tumor angiogenesis in HBV-associated hepatocellular carcinoma (HCC). Moreover, COX-2 up-regulates VEGF expression in HCC-cells, possibly via prostaglandins production. Selective inhibition of COX-2 may block HCC associated angiogenesis and provide a rational approach for treatment of this malignancy [20] .
Therefore, VEGF may serve as either a stimulator or regulator in the biological process of angiogenesis. On the other hand, the use of COX-2 inhibitor may compromise VEGF-mediated physiological response. As we previously suggested, under ischemia or hypoxia VEGF expression and secretion in cardiac myocytes is enhanced as a physiological response, and thus angiogenesis is induced to protect cardiac myocytes [10] . In this case, the use of COX-2 inhibitor may impair the cardioprotective effect of VEGF. Since the utilization of HUVECs as an in vitro model system to study endothelial functions have provided valuable insight into the potential mechanisms that underlie the microvascular dysfunction and tissue injury in vivo [16] , our observation may help us to understand one of the possible causes as to why the use of COX-2 inhibitors in the clinical setting increased the risk of cardiovascular events.
In conclusion, our present study shows that VEGF, a regulator of vasculogenesis and angiogenesis, increases COX-2 gene regulation at both mRNA and protein levels in cultured human vascular endothelial cells through p38 MAPK and JNK signal pathways. The involvement of COX-2 in VEGF-induced angiogenic response in vitro suggests that COX-2 may play a cardioprotective role in ischemic heart disease.
